Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; the references it cites are not checked yet; 42 of the 126 sources its claims cite were checked for support.

Primary and acquired resistance to EGFR-targeted therapies in colorectal cancer: impact on future treatment strategies

Open access
Leto, Simonetta M., Trusolino, Livio · 2014 · Journal of Molecular Medicine

Abstract

Only approximately 10% of genetically unselected patients with chemorefractory metastatic colorectal cancer experience tumor regression when treated with the anti-epidermal growth factor receptor (EGFR) antibodies cetuximab or panitumumab ("primary" or "de novo" resistance). Moreover, nearly all patients whose tumors initially respond inevitably become refractory ("secondary" or "acquired" resistance). An ever-increasing number of predictors of both primary and acquired resistance to anti-EGFR antibodies have been described, and it is now evident that most of the underlying mechanisms significantly overlap. By trying to extrapolate a unifying perspective out of many idiosyncratic details, here, we discuss the molecular underpinnings of therapeutic resistance, summarize research efforts aimed to improve patient selection, and present alternative therapeutic strategies that are now under development to increase response and combat relapse.

Overview

CoChat Summary

TL;DR

This review argues that primary and acquired resistance to anti-EGFR antibodies in metastatic colorectal cancer (mCRC) substantially overlap, with resistant subclones often preexisting and selected under therapy. It summarizes biomarkers and preclinical/clinical strategies proposed to improve patient selection and delay or overcome relapse.

Key findings

  • In genetically unselected chemorefractory mCRC, cetuximab or panitumumab monotherapy produces response rates of approximately 10%; KRAS exon 2 mutations occur in approximately 40–45% of CRCs and predict primary resistance, and excluding KRAS exon 2 mutants raises responders to 13–17%, though most KRAS wild-type tumors still do not respond.
  • Acquired resistance typically occurs within 3–18 months after treatment initiation; KRAS point mutations and gene copy number gains account for 38–60% of patients who relapse on cetuximab or panitumumab, and ctDNA can identify KRAS alterations 5–10 months before radiographic progression.
  • Primary and acquired resistance mechanisms overlap: HER2 amplification was present in 14% of pretreatment tumor cells and increased to 71% posttreatment; MET amplification was found in 3 of 7 patients with acquired resistance and detectable in cell-free DNA as early as 3 months after therapy start; EGFR S492R abrogates cetuximab but not panitumumab binding; no PI3K/AKT pathway alterations had been associated with acquired resistance at the time of review.
  • Therapeutic implications include BRAF inhibitor monotherapy response rates of 5% in BRAF-mutant CRC versus 48–67% in BRAF V600E-mutant melanoma; combined EGFR/BRAF inhibition was synergistic preclinically; dual HER2/EGFR targeting induced long-lasting tumor regression in HER2-amplified xenopatients; MET inhibition achieved long-lasting abolition of tumor growth in MET-positive models.

Methods

  • Narrative review appraising current knowledge on primary and acquired resistance to anti-EGFR monoclonal antibodies in mCRC, from mechanistic exploration to clinical applications, and summarizing biomarkers and alternative strategies in Table 1.
  • Evidence base includes preclinical cell lines, mouse xenografts and GEMMs, patient-derived xenografts/xenopatients, retrospective patient analyses, clinical trials/case reports, and circulating tumor DNA studies; no primary patient cohort or systematic search is described.

Limitations

  • Stated in the paper: mutant KRAS is the only validated biomarker in routine practice for selecting mCRC patients for EGFR-targeted therapies; many candidate biomarkers require prospective validation; PTEN expression analysis lacks a consensus method; and EGFR FISH in mCRC still needs interlaboratory standardization.
  • Stated in the paper: tumor biopsy may not represent intratumoral and intermetastatic heterogeneity, posttreatment tumor tissue is almost invariably unavailable, and mechanisms of ctDNA release and whether multiple metastases shed ctDNA homogeneously remain unclear.
  • Evident from the text: this is a narrative review rather than a systematic review or meta-analysis, with no formal quality assessment or quantitative synthesis; conclusions rely on heterogeneous preclinical and retrospective data.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1007/s00109-014-1161-2

Cites

Statistics

Nothing to recompute.

Figures

Fig. 1 EGFR signaling pathways. a Upon ligand binding and consequent homo- and hetero-dimerization, ErbB family members can activate a number of pathways, including the RAS-RAF-MEK-ERK and the PI3K-AKT-mTOR axes, the SRC family kinases (SFKs), PLCγ-PKC, and STATs, driving cell proliferation and/or influencing apoptosis. b By binding the extracellular domain of EGFR, both cetuximab and panitumumab prevent ligand-induced activation of downstream signaling
Fig. 1 EGFR signaling pathways. a Upon ligand binding and consequent homo- and hetero-dimerization, ErbB family members can activate a number of pathways, including the RAS-RAF-MEK-ERK and the PI3K-AKT-mTOR axes, the SRC family kinases (SFKs), PLCγ-PKC, and STATs, driving cell proliferation and/or influencing apoptosis. b By binding the extracellular domain of EGFR, both cetuximab and panitumumab prevent ligand-induced activation of downstream signalingCC BY · PubMed Central
Fig. 2 Mechanisms of resistance to anti-EGFR moAbs in mCRC. a Activating mutations of EGFR effectors, such as KRAS (by either point mutations or gene amplification), BRAF and PI3KCA, or PTEN loss of function, cause persistent activation of downstream signaling despite EGFR inhibition. b Aberrant activation (by either receptor gene amplification or high ligand levels) of alternative receptors, such as HER2 or MET (not shown), can bypass EGFR inhibition and mediate downstream pathway activation. c Additional genetic alterations within the target oncogene may abrogate drug binding. The EGFR S492R mutation inhibits cetuximab but not panitumumab binding, mediating acquired resistance to the former but not the latter in mCRC patients. d Other mechanisms of resistance may be “pathway independent,” such as altered angiogenesis (through increased secretion of VEGF or activation of VEGFR-1/2), dysregulation of EGFR recycling (with consequent increase of EGFR degradation), or tumor-stroma interactions (i.e., through increased release of antiapoptotic growth factors and cytokines, such as HGF)
Fig. 2 Mechanisms of resistance to anti-EGFR moAbs in mCRC. a Activating mutations of EGFR effectors, such as KRAS (by either point mutations or gene amplification), BRAF and PI3KCA, or PTEN loss of function, cause persistent activation of downstream signaling despite EGFR inhibition. b Aberrant activation (by either receptor gene amplification or high ligand levels) of alternative receptors, such as HER2 or MET (not shown), can bypass EGFR inhibition and mediate downstream pathway activation. c Additional genetic alterations within the target oncogene may abrogate drug binding. The EGFR S492R mutation inhibits cetuximab but not panitumumab binding, mediating acquired resistance to the former but not the latter in mCRC patients. d Other mechanisms of resistance may be “pathway independent,” such as altered angiogenesis (through increased secretion of VEGF or activation of VEGFR-1/2), dysregulation of EGFR recycling (with consequent increase of EGFR degradation), or tumor-stroma interactions (i.e., through increased release of antiapoptotic growth factors and cytokines, such as HGF)CC BY · PubMed Central
Fig. 3 Overlap between molecular biomarkers of primary and acquired resistance in mCRC. Most of the primary and acquired mechanisms of resistance to EGFR-targeted therapies in mCRC overlap. To date, no alterations of the PI3K pathway have been associated with acquired resistance; on the contrary, EGFR mutations have never been detected before exposure to EGFR monoclonal antibodies
Fig. 3 Overlap between molecular biomarkers of primary and acquired resistance in mCRC. Most of the primary and acquired mechanisms of resistance to EGFR-targeted therapies in mCRC overlap. To date, no alterations of the PI3K pathway have been associated with acquired resistance; on the contrary, EGFR mutations have never been detected before exposure to EGFR monoclonal antibodiesCC BY · PubMed Central

Verification

Claims the paper makes

20 Valid · 1 Not valid · 36 Not checked · 11 Own results and interpretations

48 more claims · 15 with their cited sources checked

Create a free account to see all 68 claims and to verify the 84 references still open.

See all claims — free account
  • It may state two separate claims as one. 13
  • Probably not a substantial claim. 3

Create a free account to see these claims.

Citations

The citation lists haven’t been fetched yet

References 147 · Cited by 87

Metadata

Authors
Leto, S. M., & Trusolino, L.
Affiliations
  • University of Turin (IT)
  • Candiolo Cancer Institute (IT)
Corresponding author
Trusolino, Livio
Venue
Journal of Molecular Medicine
Published
2014-05-10
Volume
92
Issue
7
Pages
709-722
ISSN
  • 0946-2716 (ISSN-L)
  • 1432-1440
OpenAlex
W2086061799
Cited by
87
References
147
Citations by year
2025: 2 · 2024: 7 · 2023: 7 · 2022: 5 · 2021: 9 · 2020: 7 · 2019: 12 · 2018: 10 · 2017: 7 · 2016: 10 · 2015: 8 · 2014: 3
FWCI
1.06
Type
journal article
Language
en
Open access
Locations
  • Journal of Molecular Medicine (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Institutional Research Information System University of Turin (University of Turin) (submittedVersion, cc-by)
Funders
Associazione Italiana per la Ricerca sul Cancro (14205)
Topics
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
  • Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Keywords
anti-EGFR therapy, cetuximab, panitumumab, acquired drug resistance, primary resistance, metastatic colorectal cancer, anti-EGFR monoclonal antibody, predictive biomarkers, patient selection, molecular mechanisms of resistance
MeSH terms
Animals, Antibodies, Monoclonal, Antineoplastic Agents, Humans, Protein-Tyrosine Kinases, Biomarkers, Tumor, Colorectal Neoplasms, Drug Resistance, Neoplasm

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-06, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-06 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Primary and acquired resistance to EGFR-targeted therapies in colorectal cancer: impact on future treatment strategies. https://app.cochat.ai/papers/10.1007/s00109-014-1161-2
The paper
Leto, S. M., & Trusolino, L. (2014). Primary and acquired resistance to EGFR-targeted therapies in colorectal cancer: impact on future treatment strategies. Journal of Molecular Medicine. https://doi.org/10.1007/s00109-014-1161-2

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.